https://www.biospace.com/press-releases/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study-of-vobra-duo-in-mcrpc-patients-at-esmo-congress-2024
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in...
https://www.fiercebiotech.com/biotech/gilead-grabs-hold-macrogenics-bispecific-176-billion-collaboration
Gilead offers $1.76B for option to MacroGenics' bispecific
Oct 17, 2022 - Gilead is coughing up $1.7 billion in biobucks for licensing rights to MacroGenics phase 1 bispecific for blood cancer patients.
gileadoffers1optionmacrogenics
https://www.benzinga.com/insights/analyst-ratings/24/02/37120876/decoding-4-analyst-evaluations-for-macrogenics
Decoding 4 Analyst Evaluations For Macrogenics - Macrogenics (NASDAQ:MGNX) - Benzinga
decoding4analystevaluationsmacrogenics
https://www.biospace.com/macrogenics-provides-update-on-corporate-progress-and-first-quarter-2020-financial-resultsconference-call-scheduled-for-today-at-4-30-p-m-et
MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial...
May 6, 2020 - MacroGenics, Inc. provided an update on its corporate progress and reported financial results for the quarter ended March 31, 2020.
first quartermacrogenicsprovidesupdatecorporate
https://www.biospace.com/macrogenics-to-participate-in-upcoming-june-2024-investor-conference
MacroGenics to Participate in Upcoming June 2024 Investor Conference - BioSpace
Jun 12, 2024 - MacroGenics, Inc., a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for...
to participatejune 2024investor conferencemacrogenicsupcoming
https://www.insidermonkey.com/blog/should-you-buy-macrogenics-inc-mgnx-398187/
Should You Buy MacroGenics Inc (MGNX)? - Insider Monkey
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1...
you buymacrogenicsincmgnxinsider
https://www.globenewswire.com/news-release/2021/09/12/2295423/0/en/MacroGenics-Announces-Presentations-at-ESMO-2021-Virtual-Annual-Congress.html
MacroGenics Announces Presentations at ESMO 2021 Virtual
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing...
macrogenicsannouncespresentationsesmo2021
https://www.fool.com/investing/2019/10/23/why-macrogenics-is-tanking-today.aspx
Why MacroGenics Is Tanking Today | The Motley Fool
Oct 23, 2019 - Shares sink after the company provides investors with a clinical update. Here are the must-know details.
is tankingmacrogenicstodaymotleyfool
https://www.epo.org/fr/boards-of-appeal/decisions/t161856eu1
T 1856/16 (Antibodies with variant Fc regions/MACROGENICS) du 24.08.2020
https://www.prnewswire.co.uk/news-releases/agc-biologics-enters-into-commercial-supply-agreement-with-macrogenics-682287592.html
AGC Biologics enters into Commercial Supply Agreement with MacroGenics
/PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that in late 2017 it entered...
agc biologicscommercial supplyentersagreementmacrogenics
https://www.macrotrends.net/stocks/charts/MGNX/macrogenics/price-sales
MacroGenics Price to Sales Ratio 2012-2026 | MGNX | MacroTrends
price to sales ratiomacrogenics20122026mgnx
https://www.biospace.com/macrogenics-announces-achievement-of-25-million-in-milestones-related-to-retifanlimab-collaboration-with-incyte
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab...
Nov 30, 2020 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based...
25 millionrelated tomacrogenicsannouncesachievement
https://www.macrotrends.net/stocks/charts/MGNX/macrogenics/return-on-tangible-equity
MacroGenics Return on Tangible Equity 2012-2025 | MGNX | MacroTrends
Current and historical return on tangible equity values for MacroGenics (MGNX) over the last 10 years. Return on tangible equity can be defined as the amount...
return on tangible equitymacrogenics20122025mgnx
https://www.fool.com/investing/2020/12/17/why-macrogenics-stock-soared-then-sank-today/
Why MacroGenics Stock Soared Then Sank Today | The Motley Fool
Dec 17, 2020 - There were different reactions to the company's first FDA approval.
macrogenicsstocksoaredsanktoday
https://www.fool.com/investing/general/2016/05/18/why-charter-communications-macrogenics-and-td-amer.aspx
Why Charter Communications, MacroGenics, and TD Ameritrade Jumped Today | The Motley Fool
May 18, 2016 - Find out what pushed these stocks up on a flat market day.
why chartertd ameritrade
https://investorplace.com/stock-quotes/mgnx-stock-quote/
Macrogenics (MGNX) Latest News & Price | InvestorPlace
Check out our MGNX stock analysis, current MGNX quote, charts, and historical prices for Macrogenics stock
latest newsmacrogenicsmgnxpriceinvestorplace
https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/macrogenics-announces-pricing-public-offering-common-stock/
MacroGenics Announces Pricing of Public Offering of Common Stock | INN
Jan 5, 2026 - MacroGenics (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics...
public offeringcommon stockmacrogenicsannouncespricing
https://www.biospace.com/press-releases/macrogenics-provides-update-on-corporate-progress-and-first-quarter-2025-financial-results
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results -...
https://www.home.saxo/fr-be/markets/stocks/mgnx-xnas
Macrogenics Inc. action | Saxo Bank
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer.
macrogenicsincactionsaxobank